Share This:
Search Results
The DNTP Technical Report (TR) Level of Evidence Criteria are available here: https://ntp.niehs.nih.gov/go/baresults. In the table below this information is further delineated into three fields:
- Level of Evidence: The overall category of evidence of carcinogenic activity for the TR, Species, Strain and Sex
- Organ Site Call: The level of evidence supported by the specific organ site for the TR, Species, Strain and Sex. When the Organ Site Call directly supports the TR Level Of Evidence the Finding Type flag is set to “Neoplastic Lesion”. Some Organ Site Calls could support a separate call of Equivocal Evidence; this is noted in Finding Type by the flag “May Have Been Related”
- Finding Type: Further identification of the Organ Site Call. Where this says “Neoplastic Lesion” the Organ Site Call supports the TR Level of Evidence and the Organ Site Call is the same as that of the TR. Where Finding Type says “May Have Been Related” the TR Level of Evidence for other responses led to an overall call of Clear or Some Evidence but the specified organ supports a call of Equivocal Evidence.
| Exact Match | Publication No. | CASRN | Test Article Name | Species | Strain | Sex | Route | Organ | Level of Evidence | Organ Site Call | Tumor Type/Incidence | Finding Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yes | TR-032 | 3778-73-2 | Isophosphamide | Rats | Sprague Dawley | Female | Intraperitoneal Injection | Uterus/Cervix | Positive | Positive | (LEIOMYOSARCOMA) | Neoplastic Lesions |
| Yes | TR-019 | 366-70-1 | Procarbazine hydrochloride | Mice | B6C3F1 | Female | Intraperitoneal Injection | Uterus/Cervix | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| Yes | TR-055 | 107-06-2 | 1,2-Dichloroethane | Mice | B6C3F1 | Female | Gavage | Uterus/Cervix | Positive | Positive | (POLYP, SARCOMA) | Neoplastic Lesions |
| Yes | TR-047 | 139-65-1 | 4,4'-Thiodianiline | Rats | F344/N | Female | Dosed-Feed | Uterus/Cervix | Positive | Positive | ADENOCARCINOMA | Neoplastic Lesions |
| Yes | TR-093 | 6109-97-3 | 3-Amino-9-ethylcarbazole HCl | Rats | F344/N | Female | Dosed-Feed | Uterus/Cervix | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| Yes | TR-078 | 21416-87-5 | ICRF-159 | Rats | Sprague Dawley | Female | Intraperitoneal Injection | Uterus/Cervix | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| Yes | TR-081 | 512-56-1 | Trimethylphosphate | Mice | B6C3F1 | Female | Gavage | Uterus/Cervix | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| Yes | TR-083 | 1596-84-5 | Daminozide | Rats | F344/N | Female | Dosed-Feed | Uterus/Cervix | Positive | Positive | (ADENOCARCINOMA, LEIOMYOSARCOMA) | Neoplastic Lesions |
| Yes | TR-128 | 91-93-0 | 3,3'-Dimethoxybenzidine-4,4'-diisocyanate | Rats | F344/N | Female | Dosed-Feed | Uterus/Cervix | Positive | Positive | (POLYP) | Neoplastic Lesions |
| Yes | TR-143 | 2243-62-1 | 1,5-Naphthalenediamine | Rats | F344/N | Female | Dosed-Feed | Uterus/Cervix | Positive | Positive | (POLYP) | Neoplastic Lesions |
| Yes | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Uterus/Cervix | Clear Evidence | Clear Evidence | CARCINOMA 0/50 0/50 1/50 OR ADENOCARCINOMA 0/50 3/50 2/50 COMBINED 0/50 3/50 3/50 | Neoplastic Lesions |
| Yes | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Uterus/Cervix | Clear Evidence | Clear Evidence | ADENOMA 0/50 0/35 1/65 1/50, ADENOCARCINOMA 1/50 0/35 0/65 3/50, COMBINED 1/50 0/35 1/65 4/50 | Neoplastic Lesions |
| Yes | TR-346 | 75-00-3 | Chloroethane | Mice | B6C3F1 | Female | Inhalation | Uterus/Cervix | Clear Evidence | Clear Evidence | ENDOMETRIAL CARCINOMA 0/49 43/50 | Neoplastic Lesions |
| Yes | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Female | Gavage | Uterus/Cervix | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 0/51 3/54; ADENOCARCINOMA 0/50 4/50 3/51 6/54; POLYP 0/50 2/50 1/51 6/54 | Neoplastic Lesions |
| Yes | TR-363 | 74-96-4 | Bromoethane (ethyl bromide) | Mice | B6C3F1 | Female | Inhalation | Uterus/Cervix | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 1/47 6/48, ADENOCARCINOMA 0/50 2/50 3/47 19/48, OR SQUAMOUS CELL CARCINOMA 0/50 1/50 1/47 3/48 COMBINED 0/50 4/50 5/47 27/48 | Neoplastic Lesions |
| Yes | TR-326 | 75-21-8 | Ethylene oxide | Mice | B6C3F1 | Female | Inhalation | Uterus/Cervix | Clear Evidence | Clear Evidence | ADENOCARCINOMA 0/49 1/47 5/49 | Neoplastic Lesions |
| Yes | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Uterus/Cervix | Clear Evidence | Clear Evidence | ADENOMA 0/60 3/45 1/75 2/59 OR CARCINOMA 0/60 1/45 1/75 0/59 COMBINED 0/60 4/45 2/75 2/59 | Neoplastic Lesions |
| Yes | TR-525 | 57117-31-4 | Toxic equivalency factor evaluation (PECDF (Pentachlorodibenzofuran)) | Rats | Harlan Sprague-Dawley | Female | Gavage | Uterus/Cervix | Some Evidence | Equivocal Evidence | CARCINOMA 1/53 1/53 0/53 1/53 5/53 2/53 1/50 | May Have Been Related |
| Yes | TR-530 | TEFBINARYMIX | Toxic equivalency factor evaluation (Binary mixture; PCB 126/PCB 153) | Rats | Harlan Sprague-Dawley | Female | Gavage | Uterus/Cervix | Clear Evidence | Equivocal Evidence | SQUAMOUS CELL CARCINOMA 1/53 1/53 1/53 4/53 0/53 | May Have Been Related |
| Yes | TR-510 | 51-79-6 | Urethane | Mice | MV | Female | Dosed-Water | Uterus/Cervix | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/48 0/47 0/48 2/46 | Neoplastic Lesions |
| Yes | TR-521 | 1746-01-6 | Toxic equivalency factor evaluation (TCDD) | Rats | Harlan Sprague-Dawley | Female | Gavage | Uterus/Cervix | Clear Evidence | Clear Evidence | SQUAMOUS CELL CARCINOMA 0/53 0/54 0/53 0/53 5/53 0/53 2/50 | Neoplastic Lesions |
| Exact Match | Publication No. | CASRN | Test Article Name | Species | Strain | Sex | Route | Organ | Level of Evidence | Organ Site Call | Tumor Type/Incidence | Finding Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No | TR-055 | 107-06-2 | 1,2-Dichloroethane | Rats | Osborne Mendel | Male | Gavage | Forestomach | Positive | Positive | (SQUAMOUS CELL CARCINOMA) | Neoplastic Lesions |
| No | TR-055 | 107-06-2 | 1,2-Dichloroethane | Mice | B6C3F1 | Female | Gavage | Lung | Positive | Positive | (ALVEOLAR/BRONCHIOLAR ADENOMA) | Neoplastic Lesions |
| No | TR-055 | 107-06-2 | 1,2-Dichloroethane | Mice | B6C3F1 | Male | Gavage | Lung | Positive | Positive | (ALVEOLAR/BRONCHIOLAR ADENOMA) | Neoplastic Lesions |
| No | TR-055 | 107-06-2 | 1,2-Dichloroethane | Mice | B6C3F1 | Female | Gavage | Mammary Gland | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| No | TR-055 | 107-06-2 | 1,2-Dichloroethane | Rats | Osborne Mendel | Female | Gavage | Mammary Gland | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| No | TR-055 | 107-06-2 | 1,2-Dichloroethane | Rats | Osborne Mendel | Male | Gavage | Subcutaneous Tissue | Positive | Positive | (FIBROMA) | Neoplastic Lesions |
| Yes | TR-055 | 107-06-2 | 1,2-Dichloroethane | Mice | B6C3F1 | Female | Gavage | Uterus/Cervix | Positive | Positive | (POLYP, SARCOMA) | Neoplastic Lesions |
| No | TR-055 | 107-06-2 | 1,2-Dichloroethane | Rats | Osborne Mendel | Male | Gavage | Vascular System (Unspecified) | Positive | Positive | (HEMANGIOSARCOMA) | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Female | Gavage | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 5/46 10/46 13/50 10/51 OR CARCINOMA 0/46 0/46 4/50 6/51 COMBINED 5/46 10/46 17/50 15/51 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Female | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 23/50 18/51 29/55; SQUAMOUS CELL CARCINOMA 0/50 46/50 49/51 49/55 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Male | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 3/52 28/51 22/54 33/56; SQUAMOUS CELL CARCINOMA 0/52 40/51 50/54 51/56 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Female | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 13/49 32/51 17/52; SQUAMOUS CELL CARCINOMA 0/50 3/49 9/51 4/52 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Male | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 29/50 33/49 38/52; SQUAMOUS CELL CARCINOMA 0/50 9/50 27/49 13/52 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Female | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 2/50 6/50 7/51 10/55 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Male | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 1/52 2/51 10/54 11/56 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Female | Gavage | Intestines (Large) | Clear Evidence | Equivocal Evidence | ADENOCARCINOMA 0/49 0/47 1/52 2/52 | May Have Been Related |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Male | Gavage | Intestines (Large) | Clear Evidence | Equivocal Evidence | ADENOCARCINOMA 0/50 0/50 2/48 1/52 | May Have Been Related |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Male | Gavage | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 2/50 20/49 21/52 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Female | Gavage | Liver | Clear Evidence | Clear Evidence | ADENOMA 6/50 9/50 8/51 31/55 OR CARCINOMA 1/50 3/50 0/51 2/55 COMBINED 7/50 11/50 8/51 31/55 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Male | Gavage | Liver | Clear Evidence | Clear Evidence | ADENOMA 11/52 18/51 21/54 29/56; CARCINOMA 13/52 24/51 24/54 31/56 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Female | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | ADENOCARCINOMA 1/50 6/49 12/52 21/52 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Male | Gavage | Oral Cavity | Clear Evidence | Equivocal Evidence | SQUAMOUS CELL PAPILLOMA 0/52 0/51 0/54 2/56 | May Have Been Related |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Female | Gavage | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL CARCINOMA 0/50 0/50 1/51 5/55 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Female | Gavage | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/50 5/49 10/52 18/52 ; SQUAMOUS CELL CARCINOMA 0/50 1/49 21/52 21/52 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Male | Gavage | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 4/50 9/49 19/52; SQUAMOUS CELL CARCINOMA 1/50 0/50 11/49 25/52 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Male | Gavage | Pancreas Acinar Cell | Clear Evidence | Clear Evidence | ADENOMA 5/50 21/50 36/49 29/52 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Male | Gavage | Preputial Gland | Clear Evidence | Clear Evidence | ADENOMA 5/49 3/47 5/49 11/50 OR CARCINOMA 0/49 3/47 3/49 5/50 COMBINED 5/49 6/47 8/49 16/50 | Neoplastic Lesions |
| Yes | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Female | Gavage | Uterus/Cervix | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 0/51 3/54; ADENOCARCINOMA 0/50 4/50 3/51 6/54; POLYP 0/50 2/50 1/51 6/54 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Female | Gavage | Zymbal Gland | Clear Evidence | Clear Evidence | CARCINOMA 0/60 1/59 0/60 4/60 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Male | Gavage | Zymbal Gland | Clear Evidence | Clear Evidence | CARCINOMA 0/60 0/60 0/59 3/60 | Neoplastic Lesions |
| No | TR-143 | 2243-62-1 | 1,5-Naphthalenediamine | Rats | F344/N | Male | Dosed-Feed | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-143 | 2243-62-1 | 1,5-Naphthalenediamine | Rats | F344/N | Female | Dosed-Feed | Clitoral Gland | Positive | Positive | (ADENOMA OR CARCINOMA) | Neoplastic Lesions |
| No | TR-143 | 2243-62-1 | 1,5-Naphthalenediamine | Mice | B6C3F1 | Female | Dosed-Feed | Liver | Positive | Positive | (ADENOMA, CARCINOMA) | Neoplastic Lesions |
| No | TR-143 | 2243-62-1 | 1,5-Naphthalenediamine | Mice | B6C3F1 | Female | Dosed-Feed | Lung | Positive | Positive | (ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA) | Neoplastic Lesions |
| No | TR-143 | 2243-62-1 | 1,5-Naphthalenediamine | Mice | B6C3F1 | Female | Dosed-Feed | Thyroid Gland C-Cell | Positive | Positive | ADENOMA OR CARCINOMA, ADENOMA | Neoplastic Lesions |
| No | TR-143 | 2243-62-1 | 1,5-Naphthalenediamine | Mice | B6C3F1 | Male | Dosed-Feed | Thyroid Gland Follicular Cell | Positive | Positive | ADENOMA | Neoplastic Lesions |
| Yes | TR-143 | 2243-62-1 | 1,5-Naphthalenediamine | Rats | F344/N | Female | Dosed-Feed | Uterus/Cervix | Positive | Positive | (POLYP) | Neoplastic Lesions |
| No | TR-093 | 6109-97-3 | 3-Amino-9-ethylcarbazole HCl | Mice | B6C3F1 | Female | Dosed-Feed | Liver | Positive | Positive | (CARCINOMA) | Neoplastic Lesions |
| No | TR-093 | 6109-97-3 | 3-Amino-9-ethylcarbazole HCl | Mice | B6C3F1 | Male | Dosed-Feed | Liver | Positive | Positive | (CARCINOMA) | Neoplastic Lesions |
| No | TR-093 | 6109-97-3 | 3-Amino-9-ethylcarbazole HCl | Rats | F344/N | Female | Dosed-Feed | Liver | Positive | Positive | (CARCINOMA) | Neoplastic Lesions |
| No | TR-093 | 6109-97-3 | 3-Amino-9-ethylcarbazole HCl | Rats | F344/N | Male | Dosed-Feed | Liver | Positive | Positive | (CARCINOMA) | Neoplastic Lesions |
| No | TR-093 | 6109-97-3 | 3-Amino-9-ethylcarbazole HCl | Rats | F344/N | Male | Dosed-Feed | Skin | Positive | Positive | (PAPILLOMA OR CARCINOMA) | Neoplastic Lesions |
| Yes | TR-093 | 6109-97-3 | 3-Amino-9-ethylcarbazole HCl | Rats | F344/N | Female | Dosed-Feed | Uterus/Cervix | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| No | TR-093 | 6109-97-3 | 3-Amino-9-ethylcarbazole HCl | Rats | F344/N | Female | Dosed-Feed | Zymbal Gland | Positive | Positive | (CARCINOMA) | Neoplastic Lesions |
| No | TR-093 | 6109-97-3 | 3-Amino-9-ethylcarbazole HCl | Rats | F344/N | Male | Dosed-Feed | Zymbal Gland | Positive | Positive | (CARCINOMA) | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Brain | Clear Evidence | Equivocal Evidence | ASTROCYTOMA 0/60 2/44 3/75 1/60 | May Have Been Related |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 5/58 15/44 13/74 16/55; CARCINOMA 2/58 17/44 41/74 30/55 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOMATOUS POLYP 0/60 0/45 1/75 2/60 OR ADENOCARCINOMA 0/60 1/45 0/75 1/60 COMBINED 0/60 1/45 1/75 3/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOMATOUS POLYP 0/60 1/45 4/75 5/60 OR ADENOCARCINOMA 0/60 4/45 11/75 8/60 COMBINED 0/60 4/45 14/75 13/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 0/60 1/44 0/75 2/60 OR CARCINOMA 0/60 0/44 0/75 1/60 COMBINED 0/60 1/44 0/75 3/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 0/60 3/45 7/74 6/60; NEOPLASTIC NODULE OR CARCINOMA 1/60 1/45 0/74 2/60 COMBINED 1/60 4/45 7/74 8/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | ADENOCARCINOMA 1/60 2/45 14/75 20/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | MESOTHELIOMA 2/60 1/45 7/75 6/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 2/60 2/45 3/75 3/60 OR SQUAMOUS CELL CARCINOMA 0/60 0/45 3/75 2/60 COMBINED 2/60 2/45 6/75 5/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/60 7/45 10/75 9/60; SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA 0/60 1/45 0/75 2/60 COMBINED 1/60 8/45 10/75 11/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Preputial Gland | Clear Evidence | Clear Evidence | ADENOMA 14/60 6/43 19/73 12/59 OR CARCINOMA 2/60 6/43 15/73 19/59 COMBINED 16/60 12/43 33/73 29/59 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/60 0/45 3/75 0/60; BASAL CELL NEOPLASMS 0/60 4/45 3/75 2/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | BASAL CELL OR SEBACEOUS GLAND NEOPLASMS 2/60 33/45 56/75 41/60; SQUAMOUS CELL NEOPLASMS 0/60 13/45 28/75 22/60 | Neoplastic Lesions |
| Yes | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Uterus/Cervix | Clear Evidence | Clear Evidence | ADENOMA 0/60 3/45 1/75 2/59 OR CARCINOMA 0/60 1/45 1/75 0/59 COMBINED 0/60 4/45 2/75 2/59 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/60 3/45 4/75 3/60 OR CARCINOMA 1/60 10/45 17/75 13/60 COMBINED 1/60 12/45 21/75 16/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/59 4/45 11/75 9/60; CARCINOMA 0/59 7/45 14/75 21/60 | Neoplastic Lesions |
| No | TR-128 | 91-93-0 | 3,3'-Dimethoxybenzidine-4,4'-diisocyanate | Mice | B6C3F1 | Female | Dosed-Feed | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-128 | 91-93-0 | 3,3'-Dimethoxybenzidine-4,4'-diisocyanate | Mice | B6C3F1 | Male | Dosed-Feed | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-128 | 91-93-0 | 3,3'-Dimethoxybenzidine-4,4'-diisocyanate | Rats | F344/N | Female | Dosed-Feed | Hematopoietic System | Positive | Positive | (LYMPHOMA OR LEUKEMIA) | Neoplastic Lesions |
| No | TR-128 | 91-93-0 | 3,3'-Dimethoxybenzidine-4,4'-diisocyanate | Rats | F344/N | Male | Dosed-Feed | Hematopoietic System | Positive | Positive | (LYMPHOMA OR LEUKEMIA) | Neoplastic Lesions |
| No | TR-128 | 91-93-0 | 3,3'-Dimethoxybenzidine-4,4'-diisocyanate | Rats | F344/N | Male | Dosed-Feed | Skin | Positive | Positive | (BASAL CELL ADENOMA, SQUAMOUS CELL CARCINOMA) | Neoplastic Lesions |
| Yes | TR-128 | 91-93-0 | 3,3'-Dimethoxybenzidine-4,4'-diisocyanate | Rats | F344/N | Female | Dosed-Feed | Uterus/Cervix | Positive | Positive | (POLYP) | Neoplastic Lesions |
| No | TR-128 | 91-93-0 | 3,3'-Dimethoxybenzidine-4,4'-diisocyanate | Rats | F344/N | Female | Dosed-Feed | Zymbal Gland | Positive | Positive | (CARCINOMA) | Neoplastic Lesions |
| No | TR-128 | 91-93-0 | 3,3'-Dimethoxybenzidine-4,4'-diisocyanate | Rats | F344/N | Male | Dosed-Feed | Zymbal Gland | Positive | Positive | (CARCINOMA) | Neoplastic Lesions |
| No | TR-047 | 139-65-1 | 4,4'-Thiodianiline | Rats | F344/N | Male | Dosed-Feed | Intestines (Large) | Positive | Positive | ADENOCARCINOMA | Neoplastic Lesions |
| No | TR-047 | 139-65-1 | 4,4'-Thiodianiline | Mice | B6C3F1 | Female | Dosed-Feed | Liver | Positive | Positive | CARCINOMA | Neoplastic Lesions |
| No | TR-047 | 139-65-1 | 4,4'-Thiodianiline | Mice | B6C3F1 | Male | Dosed-Feed | Liver | Positive | Positive | CARCINOMA | Neoplastic Lesions |
| No | TR-047 | 139-65-1 | 4,4'-Thiodianiline | Rats | F344/N | Male | Dosed-Feed | Liver | Positive | Positive | CARCINOMA | Neoplastic Lesions |
| No | TR-047 | 139-65-1 | 4,4'-Thiodianiline | Mice | B6C3F1 | Female | Dosed-Feed | Thyroid Gland Follicular Cell | Positive | Positive | ADENOMA, CARCINOMA, ADENOMA OR CARCINOMA | Neoplastic Lesions |
| No | TR-047 | 139-65-1 | 4,4'-Thiodianiline | Mice | B6C3F1 | Male | Dosed-Feed | Thyroid Gland Follicular Cell | Positive | Positive | CARCINOMA | Neoplastic Lesions |
| No | TR-047 | 139-65-1 | 4,4'-Thiodianiline | Rats | F344/N | Female | Dosed-Feed | Thyroid Gland Follicular Cell | Positive | Positive | CARCINOMA | Neoplastic Lesions |
| No | TR-047 | 139-65-1 | 4,4'-Thiodianiline | Rats | F344/N | Male | Dosed-Feed | Thyroid Gland Follicular Cell | Positive | Positive | CARCINOMA | Neoplastic Lesions |
| Yes | TR-047 | 139-65-1 | 4,4'-Thiodianiline | Rats | F344/N | Female | Dosed-Feed | Uterus/Cervix | Positive | Positive | ADENOCARCINOMA | Neoplastic Lesions |
| No | TR-047 | 139-65-1 | 4,4'-Thiodianiline | Rats | F344/N | Female | Dosed-Feed | Zymbal Gland | Positive | Positive | SQUAMOUS CELL PAPILLOMA OR CARCINOMA | Neoplastic Lesions |
| No | TR-047 | 139-65-1 | 4,4'-Thiodianiline | Rats | F344/N | Male | Dosed-Feed | Zymbal Gland | Positive | Positive | SQUAMOUS CELL PAPILLOMA OR CARCINOMA | Neoplastic Lesions |
| No | TR-363 | 74-96-4 | Bromoethane (ethyl bromide) | Rats | F344/N | Male | Inhalation | Adrenal Gland Medulla | Some Evidence | Some Evidence | PHEOCHROMOCYTOMA 8/48 23/47 17/50 21/49 OR MALIGNANT PHEOCHROMOCYTOMA 0/48 1/47 2/50 0/49 COMBINED 8/48 23/47 18/50 21/49 | Neoplastic Lesions |
| No | TR-363 | 74-96-4 | Bromoethane (ethyl bromide) | Rats | F344/N | Male | Inhalation | Brain | Some Evidence | Equivocal Evidence | GRANULAR CELL TUMOR 0/49 3/50 1/50 1/50; GLIOMA 0/49 1/50 0/50 0/50, ASTROCYTOMA 0/49 1/50 0/50 0/50, OR OLIGODENDROGLIOMA 0/49 1/50 0/50 0/50 COMBINED 0/49 3/50 0/50 0/50 | May Have Been Related |
| No | TR-363 | 74-96-4 | Bromoethane (ethyl bromide) | Rats | F344/N | Female | Inhalation | Brain | Equivocal Evidence | Equivocal Evidence | GLIOMA 0/50 1/50 1/48 3/50 | Neoplastic Lesions |
| No | TR-363 | 74-96-4 | Bromoethane (ethyl bromide) | Rats | F344/N | Male | Inhalation | Lung | Some Evidence | Equivocal Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 0/48 0/49 1/48 1/48 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/48 0/49 3/48 0/48 COMBINED 0/48 0/49 4/48 1/48 | May Have Been Related |
| No | TR-363 | 74-96-4 | Bromoethane (ethyl bromide) | Mice | B6C3F1 | Male | Inhalation | Lung | Equivocal Evidence | Equivocal Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 5/50 6/50 8/50 9/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 2/50 0/50 5/50 6/50 COMBINED 7/50 6/50 12/50 15/50 | Neoplastic Lesions |
| No | TR-363 | 74-96-4 | Bromoethane (ethyl bromide) | Rats | F344/N | Female | Inhalation | Lung | Equivocal Evidence | Equivocal Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 0/50 0/48 0/47 3/49 | Neoplastic Lesions |
| Yes | TR-363 | 74-96-4 | Bromoethane (ethyl bromide) | Mice | B6C3F1 | Female | Inhalation | Uterus/Cervix | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 1/47 6/48, ADENOCARCINOMA 0/50 2/50 3/47 19/48, OR SQUAMOUS CELL CARCINOMA 0/50 1/50 1/47 3/48 COMBINED 0/50 4/50 5/47 27/48 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Brain | Clear Evidence | Equivocal Evidence | ASTROCYTOMA 0/50 1/35 1/65 2/50 | May Have Been Related |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 5/50 5/31 12/64 12/50, CARCINOMA 2/50 6/31 12/64 15/50, COMBINED 7/50 11/31 24/64 27/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Hematopoietic System | Clear Evidence | Equivocal Evidence | MONONUCLEAR CELL LEUKEMIA 17/50 19/35 28/65 20/50 | May Have Been Related |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Hematopoietic System | Clear Evidence | Clear Evidence | MONONUCLEAR CELL LEUKEMIA 7/50 13/35 27/65 15/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOMATOUS POLYP 0/50 0/35 3/65 1/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Intestines (Large) | Clear Evidence | Clear Evidence | NEOPLASMS 0/50 1/35 6/65 8/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Intestines (Small) | Clear Evidence | Clear Evidence | ADENOCARCINOMA 0/50 0/35 1/65 3/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Intestines (Small) | Clear Evidence | Clear Evidence | NEOPLASMS 0/50 1/35 0/65 2/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 0/50 0/35 2/65 4/50, CARCINOMA 0/50 0/35 0/65 1/50, COMBINED 0/50 0/35 2/65 5/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 0/50 6/35 8/65 7/50, CARCINOMA 0/50 0/35 1/65 4/50, COMBINED 0/50 6/35 9/65 11/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 2/50 3/35 12/65 9/50, SQUAMOUS CELL CARCINOMA 0/50 1/35 8/65 6/50, COMBINED 2/50 4/35 19/65 15/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 9/35 18/65 15/50, SQUAMOUS CELL CARCINOMA 1/50 1/35 6/65 2/50, COMBINED 1/50 10/35 24/65 17/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Preputial Gland | Clear Evidence | Clear Evidence | ADENOMA 6/49 2/35 12/64 8/48, CARCINOMA 2/49 3/35 11/64 1/48, COMBINED 8/49 5/35 23/64 9/48 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 2/35 5/65 5/50, SQUAMOUS CELL CARCINOMA 0/50 0/35 1/65 0/50, COMBINED 0/50 2/35 6/65 5/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | BASAL CELL ADENOMA 2/50 8/35 23/65 26/50, BASAL CELL CARCINOMA 0/50 2/35 4/65 10/50, COMBINED 2/50 9/35 27/65 28/50; SEBACEOUS GLAND ADENOMA 0/50 1/35 7/65 3/50; SQUAMOUS CELL PAPILLOMA 2/50 3/35 5/65 8/50, SQUAMOUS CELL CARCINOMA 0/50 1/35 7/65 13/50, COMBINED 2/50 4/35 11/65 19/50 | Neoplastic Lesions |
| Yes | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Uterus/Cervix | Clear Evidence | Clear Evidence | ADENOMA 0/50 0/35 1/65 1/50, ADENOCARCINOMA 1/50 0/35 0/65 3/50, COMBINED 1/50 0/35 1/65 4/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/35 5/65 3/50, CARCINOMA 0/50 4/35 7/65 14/50, COMBINED 0/50 4/35 11/65 17/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 2/35 2/65 4/50, CARCINOMA 1/50 3/35 8/65 17/50, COMBINED 1/50 5/35 10/65 20/50 | Neoplastic Lesions |
| No | TR-346 | 75-00-3 | Chloroethane | Mice | B6C3F1 | Male | Inhalation | Unspecified | Inadequate Study | Not applicable | Not applicable | |
| No | TR-346 | 75-00-3 | Chloroethane | Rats | F344/N | Female | Inhalation | Brain | Equivocal Evidence | Equivocal Evidence | ASTROCYTOMA 0/50 3/50 | Neoplastic Lesions |
| No | TR-346 | 75-00-3 | Chloroethane | Mice | B6C3F1 | Female | Inhalation | Liver | Clear Evidence | Equivocal Evidence | ADENOMA 0/49 1/48 OR CARCINOMA 3/49 7/48 COMBINED 3/49 8/48 | May Have Been Related |
| No | TR-346 | 75-00-3 | Chloroethane | Rats | F344/N | Male | Inhalation | Skin | Equivocal Evidence | Equivocal Evidence | TRICHOEPITHELIOMA 0/49 1/46, SEBACEOUS GLAND ADENOMA 0/49 1/46, OR BASAL CELL CARCINOMA 0/49 3/46 COMBINED 0/49 5/46 | Neoplastic Lesions |
| Yes | TR-346 | 75-00-3 | Chloroethane | Mice | B6C3F1 | Female | Inhalation | Uterus/Cervix | Clear Evidence | Clear Evidence | ENDOMETRIAL CARCINOMA 0/49 43/50 | Neoplastic Lesions |
| No | TR-083 | 1596-84-5 | Daminozide | Mice | B6C3F1 | Female | Dosed-Feed | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-083 | 1596-84-5 | Daminozide | Rats | F344/N | Male | Dosed-Feed | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-083 | 1596-84-5 | Daminozide | Mice | B6C3F1 | Male | Dosed-Feed | Liver | Equivocal Evidence | Equivocal | (CARCINOMA) | Neoplastic Lesions |
| Yes | TR-083 | 1596-84-5 | Daminozide | Rats | F344/N | Female | Dosed-Feed | Uterus/Cervix | Positive | Positive | (ADENOCARCINOMA, LEIOMYOSARCOMA) | Neoplastic Lesions |
| No | TR-510 | 64-17-5 | Ethanol | Mice | MV | Female | Dosed-Water | Unspecified | Inadequate Study | Not applicable | Not applicable | |
| No | TR-510 | 64-17-5 | Ethanol | Mice | MV | Male | Dosed-Water | Unspecified | Inadequate Study | Not applicable | Not applicable | |
| No | TR-326 | 75-21-8 | Ethylene oxide | Mice | B6C3F1 | Female | Inhalation | Harderian Gland | Clear Evidence | Clear Evidence | CYSTADENOMA 1/46 6/46 8/47 | Neoplastic Lesions |
| No | TR-326 | 75-21-8 | Ethylene oxide | Mice | B6C3F1 | Male | Inhalation | Harderian Gland | Clear Evidence | Clear Evidence | CYSTADENOMA 1/43 9/44 8/42 | Neoplastic Lesions |
| No | TR-326 | 75-21-8 | Ethylene oxide | Mice | B6C3F1 | Female | Inhalation | Hematopoietic System | Clear Evidence | Clear Evidence | LYMPHOMA 9/49 6/48 22/49 | Neoplastic Lesions |
| No | TR-326 | 75-21-8 | Ethylene oxide | Mice | B6C3F1 | Female | Inhalation | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 2/49 4/48 17/49; ALVEOLAR/BRONCHIOLAR CARCINOMA 0/49 1/48 7/49 | Neoplastic Lesions |
| No | TR-326 | 75-21-8 | Ethylene oxide | Mice | B6C3F1 | Male | Inhalation | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 5/50 11/50 11/50; ALVEOLAR/BRONCHIOLAR CARCINOMA 6/50 10/50 16/50 | Neoplastic Lesions |
| No | TR-326 | 75-21-8 | Ethylene oxide | Mice | B6C3F1 | Female | Inhalation | Mammary Gland | Clear Evidence | Clear Evidence | ADENOCARCINOMA 1/49 6/48 4/49; ADENOSQUAMOUS CARCINOMA 0/49 2/48 2/49 | Neoplastic Lesions |
| Yes | TR-326 | 75-21-8 | Ethylene oxide | Mice | B6C3F1 | Female | Inhalation | Uterus/Cervix | Clear Evidence | Clear Evidence | ADENOCARCINOMA 0/49 1/47 5/49 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Brain | Clear Evidence | Clear Evidence | GLIOMA 0/50 4/50 4/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Brain | Clear Evidence | Clear Evidence | GLIOMA 0/50 5/50 6/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 3/50 7/50 7/50, ADENOCARCINOMA 0/50 1/50 0/50, OR CARCINOMA 2/50 1/50 5/50 COMBINED 5/50 9/50 12/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Epididymis | Clear Evidence | Equivocal Evidence | SARCOMA 0/50 0/50 2/50 | May Have Been Related |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 2/50 9/50 OR SQUAMOUS CELL CARCINOMA 1/50 0/50 1/50 COMBINED 1/50 2/50 10/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 4/50 8/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 3/50 COMBINED 0/50 4/50 11/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 1/50 5/50 OR SQUAMOUS CELL CARCINOMA 1/50 1/50 2/50 COMBINED 1/50 2/50 6/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Glandular Stomach | Clear Evidence | Equivocal Evidence | FIBROSARCOMA 0/50 0/50 2/50 | May Have Been Related |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 4/50 10/50 16/50 OR ADENOCARCINOMA 0/50 1/50 1/50 COMBINED 4/50 11/50 17/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 7/50 10/50 16/50 OR ADENOCARCINOMA 1/50 2/50 7/50 COMBINED 8/50 12/50 22/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Hematopoietic System | Clear Evidence | Clear Evidence | LEUKEMIA 13/50 14/50 20/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMATOUS POLYP 0/50 0/50 1/50 OR ADENOCARCINOMA 0/50 1/50 3/50 COMBINED 0/50 1/50 4/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Liver | Clear Evidence | Clear Evidence | ADENOMA 18/50 16/50 30/50 OR CARCINOMA 10/50 17/50 8/50 COMBINED 24/50 31/50 35/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 6/50 6/50 8/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 7/50 5/50 14/50 COMBINED 13/50 11/50 21/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 0/50, FIBROADENOMA 1/50 0/50 0/50, OR ADENOCARCINOMA 1/50 5/50 15/50 COMBINED 2/50 6/50 15/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 14/50 32/50 29/50; ADENOCARCINOMA 1/50 11/50 16/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 3/50 8/50 7/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | MESOTHELIOMA 3/50 34/50 39/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/50 3/50 6/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 1/50 3/50 7/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 0/50 1/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 2/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 0/50 4/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Skin | Clear Evidence | Clear Evidence | SEBACEOUS GLAND ADENOMA 0/50 0/50 1/50, BASAL CELL CARCINOMA 0/50 4/50 2/50, OR SEBACEOUS GLAND ADENOCARCINOMA 0/50 0/50 1/50 COMBINED 0/50 5/50 4/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Subcutaneous Tissue | Clear Evidence | Clear Evidence | SARCOMA 0/50 1/50 6/50 OR FIBROSARCOMA 0/50 2/50 3/50 COMBINED 0/50 3/50 9/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 0/49 OR CARCINOMA 0/50 0/50 3/49 COMBINED 0/50 1/50 3/49 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 2/50 2/50 OR CARCINOMA 1/50 2/50 5/50 COMBINED 1/50 4/50 6/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Urinary Bladder | Clear Evidence | Equivocal Evidence | CARCINOMA 0/50 1/50 1/50 | May Have Been Related |
| Yes | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Uterus/Cervix | Clear Evidence | Clear Evidence | CARCINOMA 0/50 0/50 1/50 OR ADENOCARCINOMA 0/50 3/50 2/50 COMBINED 0/50 3/50 3/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Zymbal Gland | Clear Evidence | Clear Evidence | CARCINOMA 1/50 3/50 6/50 | Neoplastic Lesions |
| No | TR-078 | 21416-87-5 | ICRF-159 | Mice | B6C3F1 | Male | Intraperitoneal Injection | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-078 | 21416-87-5 | ICRF-159 | Rats | Sprague Dawley | Male | Intraperitoneal Injection | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-078 | 21416-87-5 | ICRF-159 | Mice | B6C3F1 | Female | Intraperitoneal Injection | Hematopoietic System | Positive | Positive | (LYMPHOMA) | Neoplastic Lesions |
| Yes | TR-078 | 21416-87-5 | ICRF-159 | Rats | Sprague Dawley | Female | Intraperitoneal Injection | Uterus/Cervix | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| No | TR-032 | 3778-73-2 | Isophosphamide | Mice | B6C3F1 | Male | Intraperitoneal Injection | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-032 | 3778-73-2 | Isophosphamide | Rats | Sprague Dawley | Male | Intraperitoneal Injection | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-032 | 3778-73-2 | Isophosphamide | Mice | B6C3F1 | Female | Intraperitoneal Injection | Hematopoietic System | Positive | Positive | (LYMPHOMA) | Neoplastic Lesions |
| No | TR-032 | 3778-73-2 | Isophosphamide | Rats | Sprague Dawley | Female | Intraperitoneal Injection | Mammary Gland | Positive | Positive | (FIBROADENOMA) | Neoplastic Lesions |
| Yes | TR-032 | 3778-73-2 | Isophosphamide | Rats | Sprague Dawley | Female | Intraperitoneal Injection | Uterus/Cervix | Positive | Positive | (LEIOMYOSARCOMA) | Neoplastic Lesions |
| No | TR-019 | 366-70-1 | Procarbazine hydrochloride | Mice | B6C3F1 | Female | Intraperitoneal Injection | Brain | Positive | Positive | (NEUROBLASTOMA) | Neoplastic Lesions |
| No | TR-019 | 366-70-1 | Procarbazine hydrochloride | Mice | B6C3F1 | Male | Intraperitoneal Injection | Brain | Positive | Positive | (NEUROBLASTOMA) | Neoplastic Lesions |
| No | TR-019 | 366-70-1 | Procarbazine hydrochloride | Rats | Sprague Dawley | Female | Intraperitoneal Injection | Brain | Positive | Positive | (NEUROBLASTOMA) | Neoplastic Lesions |
| No | TR-019 | 366-70-1 | Procarbazine hydrochloride | Rats | Sprague Dawley | Male | Intraperitoneal Injection | Brain | Positive | Positive | (ADENOCARCINOMA, NEUROBLASTOMA, CARCINOMA) | Neoplastic Lesions |
| No | TR-019 | 366-70-1 | Procarbazine hydrochloride | Mice | B6C3F1 | Female | Intraperitoneal Injection | Hematopoietic System | Positive | Positive | (LYMPHOMA OR LEUKEMIA) | Neoplastic Lesions |
| No | TR-019 | 366-70-1 | Procarbazine hydrochloride | Mice | B6C3F1 | Male | Intraperitoneal Injection | Hematopoietic System | Positive | Positive | (LYMPHOMA OR LEUKEMIA) | Neoplastic Lesions |
| No | TR-019 | 366-70-1 | Procarbazine hydrochloride | Rats | Sprague Dawley | Female | Intraperitoneal Injection | Hematopoietic System | Positive | Positive | (LYMPHOMA) | Neoplastic Lesions |
| No | TR-019 | 366-70-1 | Procarbazine hydrochloride | Rats | Sprague Dawley | Male | Intraperitoneal Injection | Hematopoietic System | Positive | Positive | (LYMPHOMA OR LEUKEMIA) | Neoplastic Lesions |
| No | TR-019 | 366-70-1 | Procarbazine hydrochloride | Mice | B6C3F1 | Female | Intraperitoneal Injection | Lung | Positive | Positive | (ALVEOLAR/BRONCHIOLAR ADENOMA) | Neoplastic Lesions |
| No | TR-019 | 366-70-1 | Procarbazine hydrochloride | Mice | B6C3F1 | Male | Intraperitoneal Injection | Lung | Positive | Positive | (ALVEOLAR/BRONCHIOLAR ADENOMA) | Neoplastic Lesions |
| No | TR-019 | 366-70-1 | Procarbazine hydrochloride | Rats | Sprague Dawley | Female | Intraperitoneal Injection | Mammary Gland | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| No | TR-019 | 366-70-1 | Procarbazine hydrochloride | Rats | Sprague Dawley | Male | Intraperitoneal Injection | Mammary Gland | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| Yes | TR-019 | 366-70-1 | Procarbazine hydrochloride | Mice | B6C3F1 | Female | Intraperitoneal Injection | Uterus/Cervix | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| No | TR-530 | TEFBINARYMIX | Toxic equivalency factor evaluation (Binary mixture; PCB 126/PCB 153) | Rats | Harlan Sprague-Dawley | Female | Gavage | Liver | Clear Evidence | Clear Evidence | CHOLANGIOCARCINOMA 0/53 0/53 1/52 9/52 30/51 HEPATOCHOLANGIOMA 0/53 0/53 0/52 2/52 6/51 ADENOMA 0/53 0/53 3/52 5/52 27/51 | Neoplastic Lesions |
| No | TR-530 | TEFBINARYMIX | Toxic equivalency factor evaluation (Binary mixture; PCB 126/PCB 153) | Rats | Harlan Sprague-Dawley | Female | Gavage | Lung | Clear Evidence | Clear Evidence | CYSTIC KERATINIZING EPITHELIOMA 0/53 0/53 0/52 1/53 11/52 | Neoplastic Lesions |
| No | TR-530 | TEFBINARYMIX | Toxic equivalency factor evaluation (Binary mixture; PCB 126/PCB 153) | Rats | Harlan Sprague-Dawley | Female | Gavage | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL CARCINOMA (GINGIVAL) 0/53 0/53 2/53 5/53 9/53 | Neoplastic Lesions |
| No | TR-530 | TEFBINARYMIX | Toxic equivalency factor evaluation (Binary mixture; PCB 126/PCB 153) | Rats | Harlan Sprague-Dawley | Female | Gavage | Pancreas Acinar Cell | Clear Evidence | Clear Evidence | ADENOMA 0/53 1/53 1/52 3/52 1/50 ADENOMA OR CARCINOMA 0/53 1/53 1/52 4 /52 2/50 | Neoplastic Lesions |
| Yes | TR-530 | TEFBINARYMIX | Toxic equivalency factor evaluation (Binary mixture; PCB 126/PCB 153) | Rats | Harlan Sprague-Dawley | Female | Gavage | Uterus/Cervix | Clear Evidence | Equivocal Evidence | SQUAMOUS CELL CARCINOMA 1/53 1/53 1/53 4/53 0/53 | May Have Been Related |
| No | TR-525 | 57117-31-4 | Toxic equivalency factor evaluation (PECDF (Pentachlorodibenzofuran)) | Rats | Harlan Sprague-Dawley | Female | Gavage | Liver | Some Evidence | Some Evidence | ADENOMA 1/53 0/53 1/53 0/52 2/53 4/53 1/50 OR CHOLANGIOCARCINOMA 0/53 0/53 0/53 1/52 1/53 2/53 0/50 | Neoplastic Lesions |
| No | TR-525 | 57117-31-4 | Toxic equivalency factor evaluation (PECDF (Pentachlorodibenzofuran)) | Rats | Harlan Sprague-Dawley | Female | Gavage | Lung | Some Evidence | Equivocal Evidence | CYSTIC KERATINIZING EPITHELIOMA (MULTIPLE) 0/53 0/53 0/53 0/53 0/53 1/52 0/50 | May Have Been Related |
| No | TR-525 | 57117-31-4 | Toxic equivalency factor evaluation (PECDF (Pentachlorodibenzofuran)) | Rats | Harlan Sprague-Dawley | Female | Gavage | Oral Cavity | Some Evidence | Some Evidence | (ORAL MUCOSA) GINGIVAL SQUAMOUS CELL CARCINOMA 1/53 2/53 1/53 0/53 1/53 3/53 3/50 | Neoplastic Lesions |
| No | TR-525 | 57117-31-4 | Toxic equivalency factor evaluation (PECDF (Pentachlorodibenzofuran)) | Rats | Harlan Sprague-Dawley | Female | Gavage | Pancreas Acinar Cell | Some Evidence | Equivocal Evidence | ADENOMA OR CARCINOMA 0/53 0/53 0/53 0/52 2/52 0/52 2/49 | May Have Been Related |
| Yes | TR-525 | 57117-31-4 | Toxic equivalency factor evaluation (PECDF (Pentachlorodibenzofuran)) | Rats | Harlan Sprague-Dawley | Female | Gavage | Uterus/Cervix | Some Evidence | Equivocal Evidence | CARCINOMA 1/53 1/53 0/53 1/53 5/53 2/53 1/50 | May Have Been Related |
| No | TR-521 | 1746-01-6 | Toxic equivalency factor evaluation (TCDD) | Rats | Harlan Sprague-Dawley | Female | Gavage | Liver | Clear Evidence | Equivocal Evidence | HEPATOCHOLANGIOMA 0/53 0/54 0/53 0/53 0/53 2/53 0/50 OR CHOLANGIOMA 0/53 0/54 0/53 0/53 0/53 0/53 1/50 | May Have Been Related |
| No | TR-521 | 1746-01-6 | Toxic equivalency factor evaluation (TCDD) | Rats | Harlan Sprague-Dawley | Female | Gavage | Liver | Clear Evidence | Clear Evidence | ADENOMA 0/53 0/54 0/53 0/53 1/53 13/53 2/50 OR CHOLANGIOCARCINOMA 0/53 0/54 0/53 1/53 4/53 25/53 2/50 | Neoplastic Lesions |
| No | TR-521 | 1746-01-6 | Toxic equivalency factor evaluation (TCDD) | Rats | Harlan Sprague-Dawley | Female | Gavage | Lung | Clear Evidence | Clear Evidence | CYSTIC KERATINIZING EPITHELIOMA 0/53 0/54 0/53 0/52 0/53 9/52 0/50 | Neoplastic Lesions |
| No | TR-521 | 1746-01-6 | Toxic equivalency factor evaluation (TCDD) | Rats | Harlan Sprague-Dawley | Female | Gavage | Oral Cavity | Clear Evidence | Clear Evidence | GINGIVAL SQAMOUS CELL CARCINOMA (ORAL MUCOSA) 1/53 2/54 1/53 0/53 4/53 10/53 5/50 | Neoplastic Lesions |
| No | TR-521 | 1746-01-6 | Toxic equivalency factor evaluation (TCDD) | Rats | Harlan Sprague-Dawley | Female | Gavage | Pancreas Acinar Cell | Clear Evidence | Equivocal Evidence | ADENOMA OR CARCINOMA 0/51 0/54 0/52 0/53 0/52 3/51 1/49 | May Have Been Related |
| Yes | TR-521 | 1746-01-6 | Toxic equivalency factor evaluation (TCDD) | Rats | Harlan Sprague-Dawley | Female | Gavage | Uterus/Cervix | Clear Evidence | Clear Evidence | SQUAMOUS CELL CARCINOMA 0/53 0/54 0/53 0/53 5/53 0/53 2/50 | Neoplastic Lesions |
| No | TR-081 | 512-56-1 | Trimethylphosphate | Mice | B6C3F1 | Male | Gavage | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-081 | 512-56-1 | Trimethylphosphate | Rats | F344/N | Female | Gavage | Unspecified | Negative | Not applicable | Not applicable | |
| No | TR-081 | 512-56-1 | Trimethylphosphate | Rats | F344/N | Male | Gavage | Subcutaneous Tissue | Positive | Positive | (FIBROMA) | Neoplastic Lesions |
| Yes | TR-081 | 512-56-1 | Trimethylphosphate | Mice | B6C3F1 | Female | Gavage | Uterus/Cervix | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Male | Dosed-Water | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA 0/46 2/47 3/44 5/45 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Female | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 3/48 10/48 8/48 21/48 CARCINOMA 0/48 1/48 11/48 11/48 COMBINED 3/48 11/48 19/48 30/48 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Male | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 3/47 11/47 25/47 28/47 CARCINOMA 0/47 1/47 7/47 16/47 COMBINED 3/47 12/47 30/47 38/47 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Male | Dosed-Water | Heart | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/48 0/48 1/47 5/48 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/48 0/47 1/47 7/47 ADENOMA 5/48 10/47 19/47 18/47 ADENOMA OR CARCINOMA 5/48 11/47 20/47 19/47 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Male | Dosed-Water | Liver | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 1/46 2/47 5/46 13/44 ADENOMA 7/46 13/47 17/46 17/44 ADENOMA OR CARCINOMA 12/46 18/47 24/46 23/44 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Female | Dosed-Water | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 4/48 6/48 17/48 29/47 ALVEOLAR/BRONCHIOLAR CARCINOMA 2/48 4/48 13/48 19/47 COMBINED 6/48 8/48 28/48 39/47 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Male | Dosed-Water | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 4/48 17/48 22/47 34/48 ALVEOLAR/BRONCHIOLAR CARCINOMA 1/48 1/48 9/47 9/48 COMBINED 5/48 18/48 29/47 37/48 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | ADENOACANTHOMA 0/47 1/46 1/46 11/48 ADENOCARCINOMA 4/47 3/46 3/46 11/48 COMBINED 4/47 4/46 4/46 22/48 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Female | Dosed-Water | Ovary | Clear Evidence | Clear Evidence | BENIGN GRANULOSA CELL TUMOR 0/48 0/46 2/46 3/39 MALIGNANT GRANULOSA CELL TUMOR 0/48 0/46 0/46 3/39 COMBINED 0/48 0/46 2/46 5/39 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/48 0/48 0/46 2/48 | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA (0/47, 1/48, 5/47, 8/48) | Neoplastic Lesions |
| No | TR-510 | 51-79-6 | Urethane | Mice | MV | Female | Dosed-Water | Spleen | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/48 0/45 1/47 4/46 | Neoplastic Lesions |
| Yes | TR-510 | 51-79-6 | Urethane | Mice | MV | Female | Dosed-Water | Uterus/Cervix | Clear Evidence | Clear Evidence | HEMANGIOSARCOMA 0/48 0/47 0/48 2/46 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) ADENOMA 2/47 3/47 9/46 19/47 CARCINOMA 1/47 3/47 6/46 16/47 COMBINED 3/47 5/47 15/46 35/47 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) ADENOMA 4/48 7/48 6/46 20/46 CARCINOMA 1/48 11/48 7/46 10/46 COMBINED 5/48 18/48 13/46 29/46 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) ADENOMA 6/48 14/48 21/47 27/48 CARCINOMA 0/48 0/48 1/47 16/48 COMBINED 6/48 14/48 21/47 38/48 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) ADENOMA 5/47 12/48 15/48 26/45 CARCINOMA 0/47 2/48 2/48 10/45 COMBINED 5/47 14/48 17/48 35/45 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Heart | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) HEMANGIOSARCOMA 0/47 0/48 0/48 6/47 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Heart | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/47 0/47 0/48 3/48 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Heart | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/48 0/48 2/47 4/48 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Heart | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) HEMANGIOSARCOMA 0/47 0/48 1/48 4/48 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) HEMANGIOSARCOMA 0/48 0/47 0/48 6/48 ADENOMA 3/48 6/47 16/48 16/48 ADENOMA OR CARCINOMA 3/48 7/47 16/48 17/48 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 1/47 2/47 0/47 7/46 ADENOMA 6/47 5/47 15/47 23/46 ADENOMA OR CARCINOMA 7/47 5/47 16/47 23/46 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Liver | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) HEMANGIOSARCOMA 2/48 2/46 4/48 13/48 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Liver | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 3/47 4/48 3/46 11/48 ADENOMA 12/47 15/48 16/46 24/48 ADENOMA OR CARCINOMA 16/47 19/48 17/46 24/48 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Lung | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) ALVEOLAR/BRONCHIOLAR ADENOMA 5/47 10/47 16/48 28/48 ALVEOLAR/BRONCHIOLAR CARCINOMA 0/47 2/47 6/48 23/48 COMBINED 5/47 11/47 21/48 38/48 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Lung | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) ALVEOLAR/BRONCHIOLAR ADEMONA 5/48 10/48 18/48 30/48 ALVEOLAR/BRONCHIOLAR CARCINOMA 1/48 7/48 9/48 23/48 COMBINED 5/48 17/48 24/48 37/48 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Lung | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) ALVEOLAR/BRONCHIOLAR ADEMONA 6/48 8/48 9/48 33/48 ALVEOLAR/BRONCHIOLAR CARCINOMA 5/48 4/48 5/48 17/48 COMBINED 11/48 11/48 14/48 40/48 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Lung | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) ALVEOLAR/BRONCHIOLAR ADENOMA 10/48 16/48 19/47 35/48 ALVEOLAR/BRONCHIOLAR CARCINOMA 2/48 3/48 8/47 24/48 COMBINED 11/48 19/48 24/47 43/48 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) ADENOACANTHOMA 0/47 0/45 2/48 3/47 ADENOCARCINOMA 4/47 3/45 11/48 14/47 COMBINED 4/47 3/45 12/48 16/47 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) ADENOACANTHOMA 0/47 0/48 1/48 9/45 ADENOCARCINOMA 3/47 4/48 6/48 15/45 COMBINED 3/47 4/48 7/48 23/45 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Ovary | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) BENIGN GRANULOSA CELL TUMOR 0/46 0/47 5/46 3/45 BENIGN OR MALIGNANT GRANULOSA CELL TUMOR 0/46 0/47 6/46 3/45 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/47 0/47 0/48 2/47 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA (0/48, 1/48, 4/46, 7/47) | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | (URETHANE AND 5% ETHANOL) SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA (0/48, 2/47, 0/48, 7/48) | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Female | Dosed-Water | Spleen | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/47 0/46 0/46 3/46 | Neoplastic Lesions |
| No | TR-510 | URETHCOMB | Urethane + ethanol (combination) | Mice | MV | Male | Dosed-Water | Spleen | Clear Evidence | Clear Evidence | (URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/46 0/46 1/46 3/46 | Neoplastic Lesions |